Effect of calcium channel blockers on incidence of diabetes: a meta-analysis

References

• Elliott WJ Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 2007 369 9557 201 207 17240286
   PubMed Web of Science ®Google Scholar
• Xu G Chen J Jing G Shalev A Preventing #beta-cell loss and diabetes with calcium channel blockers Diabetes 2012 61 4 848 856 22442301
   PubMed Web of Science ®Google Scholar
• Schulz KF Altman DG Moher D CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials Int J Surg 2011 9 8 672 677 22019563
   PubMed Web of Science ®Google Scholar
• Moher D Cook DJ Eastwood S Olkin I Rennie D Stroup DF Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM Statement Onkologie 2000 23 6 597 602 11441269
   PubMed Web of Science ®Google Scholar
• Thompson SG Higgins JP How should meta-regression analyses be undertaken and interpreted? Stat Med 2002 21 11 1559 1573 12111920
   PubMed Web of Science ®Google Scholar
• Liberati A Altman DG Tetzlaff J The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 2009 151 4 W65 W94 19622512
   PubMed Web of Science ®Google Scholar
• Thornley-Brown D Wang X Wright JT Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease Arch Intern Med 2006 166 7 797 805 16606818
   PubMedGoogle Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 2002 288 23 2981 2997 12479763
   PubMed Web of Science ®Google Scholar
• Dahlöf B Sever PS Poulter NR ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial Lancet 2005 366 9489 895 906 16154016
   PubMed Web of Science ®Google Scholar
• Liu L Zhang Y Liu G FEVER Study Group The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo- controlled trial in Chinese hypertensive patients J Hypertens 2005 23 12 2157 2172 16269957
   PubMed Web of Science ®Google Scholar
• Brown MJ Palmer CR Castaigne A Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 2000 356 9227 366 372 10972368
   PubMed Web of Science ®Google Scholar
• Pepine CJ Handberg EM Cooper-DeHoff RM INVEST Investigators A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial JAMA 2003 290 21 2805 2816 14657064
   PubMed Web of Science ®Google Scholar
• Hansson L Hedner T Lund-Johansen P Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 2000 356 9227 359 365 10972367
   PubMed Web of Science ®Google Scholar
• Hansson L Lindholm LH Ekbom T Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study Lancet 1999 354 9192 1751 1756 10577635
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE Julius S Mancia G VALUE Trial Investigators Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial J Hypertens 2006 24 7 1405 1412 16794491
   PubMed Web of Science ®Google Scholar
• Ogihara T Nakao K Fukui T Candesartan Antihypertensive Survival Evaluation in Japan Trial Group Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 2008 51 2 393 398 18172059
   PubMed Web of Science ®Google Scholar
• Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives National Intervention Cooperative Study in Elderly Hypertensives Study Group Hypertension 1999 34 5 1129 1133 10567194
   PubMed Web of Science ®Google Scholar
• Kaneshiro Y Ichihara A Sakoda M Kurauchi-Mito A Kinouchi K Itoh H Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan Kidney Blood Press Res 2009 32 1 51 58 19258723
   PubMed Web of Science ®Google Scholar
• Mancia G De Backer G Dominiczak A ESH-ESC Task Force on the Management of Arterial Hypertension 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 2007 25 9 1751 1762 17762635
   PubMed Web of Science ®Google Scholar
• Chobanian AV Bakris GL Black HR National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 2003 289 19 2560 2572 12748199
   PubMed Web of Science ®Google Scholar
• Kuti EL Baker WL White CM The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker Curr Med Res Opin 2007 23 6 1239 1244 17559720
   PubMed Web of Science ®Google Scholar